Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Would Legalizing Medical Marijuana Help Curb the Opioid Epidemic?

Ronnie Cohen  |  March 28, 2017

Many of Bachhuber’s patients ask for help quitting highly addictive opioids, and some have used marijuana to taper off the prescription painkillers, he said.

Nonetheless, a 1970 federal law puts cannabis in the same category as heroin, Schedule 1 of the Comprehensive Drug Abuse Prevention and Control Act, and finds it has no medicinal value. Consequently, doctors can only recommend, not prescribe, marijuana, and physicians who work for the federal government cannot even discuss the weed.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Federal prohibition also has led to severe limitations on marijuana research.

In January, a National Academies report found conclusive or substantial evidence that cannabis can effectively treat chronic pain, chemotherapy-induced nausea and spasticity. The report, written by an independent panel of medical experts, found no evidence of cannabis overdose deaths.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

It did, however, find links between cannabis use and an increased risk of vehicle accidents, as well as the development of schizophrenia or other psychoses, particularly among the most frequent users.

Bachhuber lamented the dearth of research on the best ways to use marijuana as medicine.

“We have information that it works based on the National Academies’ report,” he says. “But we don’t know who it works best for, at what dosage, for how long.”

Last week, U.S. Attorney General Jeff Sessions, the nation’s top cop, reiterated his concerns about marijuana and heroin, an illegal opioid.

“I am astonished to hear people suggest that we can solve our heroin crisis by legalizing marijuana,” he told law enforcement officers in Virginia, “so people can trade one life-wrecking dependency for another.”


Reference

  1. Shi Y. Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug Alcohol Depend. 2017 Apr 1;173:144–150. doi: 10.1016/j.drugalcdep.2017.01.006. Epub 2017 Feb 21.

Page: 1 2 | Single Page
Share: 

Filed under:AnalgesicsDrug Updates Tagged with:DrugsmarijuanaOpioid abuseOpioids

Related Articles

    Cannabis in Rheumatology Care: A Look at the Latest Research & What Rheumatologists Are Telling Their Patients

    March 26, 2018

    As medical and recreational marijuana becomes more accessible, researchers seek creative ways to study the cannabis plant and explore the complexities of the endocannabinoid system in pain relief. Rheumatologists currently face an influx of patients asking if marijuana can help them. Here’s a look at the evolving research on cannabinoids for rheumatologic pain management and how doctors are discussing it with their patients…

    Cannabis for Pain Relief: An Area Ripe for Research

    September 28, 2023

    Medical cannabis may benefit patients experiencing pain, and rheumatologists should be able to discuss its potential risks and benefits with their patients. Here are insights from Dr. Mary Ann Fitzcharles on current research, patient use and more.

    Brandon Crawford / shutterstock.com

    Case Report: Blunt Smoker Denies Tobacco Use, Delaying Diagnosis

    May 12, 2022

    Cannabis arteritis mirrors thrombo­angiitis obliterans in its clinical and arteriographic presentation, but its relevant exposure is cannabis rather than tobacco.1 Whether cannabis arteritis is a subset of thromboangiitis obliterans or a unique pathologic entity is debatable. Delta-9-tetrahydrocannabinol, the primary psychoactive component of cannabis, is a peripheral vasoconstrictor.2 This offers mechanistic insight into how cannabis may…

    Marijuana for Rheumatology Patients?

    February 17, 2018

    SAN DIEGO—What does cannabis offer to the treatment and management of rheumatology patients and the range of pain states they experience? What do we really know about its long-term effects? These are hard questions to answer with currently available data and a reality nuanced by complications cannabis advocates don’t always recognize, according to two experts…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences